Scholars Central

Conference abstractPublished 21 Jul 2021

Landscape Genomics and Signature Selection to Understand the Genetic Adaptation of Indigenous Cattle

Authors: Filipa Sousa, Joana Oliveira, Ines Gante, Margarida Dias

Gynecology Departement Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Ovarian surgical ablation (OSA) in estrogen receptor-positive (ER+) breast cancer is usually performed to halt ovarian function in premenopausal patients. Since alternative pharmacological therapy exists and few studies have investigated why surgery is still performed, we aimed to analyze the reasons for the use of OSA despite the remaining controversy. Materials and Methods: Premenopausal ER+ breast cancer patients treated at a tertiary center (2005– 2011) were selected, and patients with germline mutations were excluded. Results: Seventy-nine patients met the inclusion criteria. Globally, the main reasons for OSA included: continued men- struation despite hormone therapy with or without ovarian medical ablation (OMA) (34.2%), pa- tient informed choice (31.6%), disease progression (16.5%), gynecological disease requiring sur- gery (13.9%), and tamoxifen intolerance/contraindication (3.8%). In women aged ≥45 years, patient choice was significantly more frequently the reason for OSA (47.4% versus 17.1% (p = 0.004)). For those aged <45 years, salvation attempts were significantly more frequent as compared to older women (26.8% versus 5.3% (p = 0.01)). In 77.8% of women undergoing OSA with menstrual cycle maintenance, surgery was performed 1–5 years after diagnosis, while surgery was performed earlier (0–3 months after diagnosis) in patients undergoing OSA as an informed choice (56.0%), as a salvation attempt (53.8%), or due to gynecological disease (63.6%). The leading reason for OSA in women previously undergoing OMA was continued menstruation (60.0%). Conclusions: This study suggests a possible failure of pharmacological ovarian suppression and reinforces the need for shared decisionmaking with patients when discussing treatment strategies, although valida- tion by further studies is warranted due to our limited sample size.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Gynecology & Obstetrics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalGynecology & Obstetrics
  • SubjectReproductive Medicine & Gynaecology
  • BylineArticles whose byline prints “Filipa Sousa”
  • BylineArticles whose byline prints “Joana Oliveira”
  • BylineArticles whose byline prints “Ines Gante”
  • BylineArticles whose byline prints “Margarida Dias”